As antiretroviral therapy (ART) prolongs lifespans, people with HIV (PWH) face a new syndemic: Cardiovascular-Kidney-Metabolic (CKM) syndrome. Yet CKM in PWH is poorly characterized. Inflammation, complex pharmacokinetic alterations, ART-associated metabolic effects, and gut dysbiosis amplify risk. Managing CKM increases medication burden, thereby heightening the risk of drug–drug interactions and adverse drug effects. Therefore, CKM in PWH represents an emerging clinical pharmacology priority.
A perspective, published in Clinical Pharmacology & Therapeutics, outlines gaps and challenges and call for CKM research in PWH.
Source : Clinical Pharmacology & Therapeutics
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.